Kiddo, not sure of the POM, but I seem to remember PAB stating a couple of yrs ago that the reason why there arn't many cos. working on 'natural antbodies' is because of the difficulty in manufacturing in sufficient quantities. I suppose difficulty could be related to price to some extent. PAB have since stated they have been successful in manufacturing, at least in quantites sufficient for Phase 1/11a trial.
My only concern is the contradictory statements, five weeks we were dosing, yesterday we we recruiting. Which is it?
There is, of course one possible answer that both are correct. That is, we may be dosing one or two and recruiting the other(s). But I doubt that. Still have faith and intend taking up my rights, unless, of course!!!!
situation update, page-74
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $12.34M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 4383931 | 0.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.7¢ | 1884285 | 5 |
View Market Depth
| Last trade - 16.12pm 10/09/2024 (20 minute delay) ? |
| PAB (ASX) Chart |
Day chart unavailable